HLB is taking control of changes of the future in various business fields, with
constant efforts and passion.
Apatinib — new third-line option for refractory gastric or GEJ cancer
Author : Toru Aoyama & Takaki Yoshikawa
Source : NATURE-REVIEWS
Apatinib significantly improves both the progression-free survival (PFS) and overall survival in patients with advanced-stage gastric cancer who are
refractory to two or more lines of chemotherapy. In the context of previous phase III trials of angiogenesis inhibitors for this disease, we discuss the role
of apatinib, and the advantages and limitations of VEGFR‑2 blockade in the advanced disease setting.